CClinicalTrials.gg
RecruitingNCT06563726SALTUpdated May 28, 2025

Sodium Awareness in Lactation Trial

An interventional study of point-of-care milk sodium testing in Breastfeeding, Preterm Birth and Breast Pumping, sponsored by The Hospital for Sick Children. Recruiting at 2 sites in United States. Open to female participants. Per ClinicalTrials.gov, last updated 2025-05-28.

Sponsored by The Hospital for Sick Children · Not applicable, Interventional, and Diagnostic

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Mar 2025; still recruiting 1 year 6 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Sex
Female
01

Study summary

SALT is a multi-centre, non-blinded, non-randomized prospective interventional pilot study teaching lactating parents of hospitalized preterm infants how to test their breastmilk sodium (Na) using point-of-care (POC) meters. A drop in Na is a sign of secretory activation in the breast that is associated with adequate short and long-term breast milk volumes in this vulnerable population.

Primary Objective: Establish feasibility, acceptance, and time cost of parent-led parent milk Na testing in the first 14 days postpartum

Secondary Objective: Further investigate relationships between pumping behaviours, lactation risk factors, daily milk Na and lactation outcomes

Exploratory Objective: Explore how POC Na data may be used to modify pumping behaviour and milk volumes

02

Conditions studied

  • Breastfeeding
  • Preterm Birth
  • Breast Pumping
  • Lactation; Insufficient, Partial

Browse trials for

03

In context

Premature Birth

2,554 studies on the registry are indexed under Premature Birth; 498 are open to participants now.

This study's planned enrollment of 40 is below the median of 84 across 1,689 interventional studies indexed under Premature Birth.

Browse Premature Birth studies →

Lead sponsor

The Hospital for Sick Children is the lead sponsor of 568 studies on the registry; 81 are open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  1. Consent provided
  2. Have delivered a preterm singleton or twin infant at \<35 weeks gestation admitted to a study NICU at birth or transferred into a study NICU from another NICU within the first 72 hours postpartum
  3. Day 5 or less postpartum (Day 1 = day of delivery) upon enrollment (ideally day 3 or less)
  4. Plans to lactate at least 2 weeks and initiate lactation with a breast pump
  5. Expected infant NICU stay of 7+ (ideally 14+) days in enrollment NICU(s)

Exclusion criteria

Exclusion Criteria:

  1. Potential study participant's infant is critically ill and not expected to survive or has lethal diagnosis with plans by medical team/family to redirect care
  2. Has delivered triplets or higher order multiples (potential confounder for lactation challenges; of note, triplets or higher are rare, on the order of a few parents annually)
  3. Lactation contraindication(s) (i.e., active chemotherapy) or declines lactation initiation
  4. History of breast surgery that may affect ability to lactate (i.e., breast reduction; breast augmentation that utilized nipple incisions)
  5. Using or planning to use hormonal birth control in the first 14 days post-partum as may affect secretory activation/lactation
  6. Unable/unwilling to be present in study NICU during any of first 5 days postpartum
  7. Presumption by the medical team that infant will be in study NICU for \<5 days
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Interventions

  • Diagnostic testpoint-of-care milk sodium testing

    Data-driven interventions to improve early lactation success are lacking, and parents who deliver preterm are at high risk of lactation challenges. We will be studying feasibility, acceptability, and time cost of teaching lactating parents of hospitalized preterm infants how to test their breastmilk sodium (Na) using point-of-care (POC) meters. As a secondary aim, we will assess the potential to use these POC sodium results to guide personalized lactation care in the form of altered pumping schedules in an attempt to reduce breastmilk Na. A drop in Na is a sign of secretory activation in the breast that is associated with adequate short and long-term breast milk volumes in this vulnerable population.

06

What researchers measure

Primary outcomes

  1. Establish feasibility of parent-led longitudinal parent milk Na testing in the first 14 days postpartum: economic

    We will collect time cost of milk testing, including teaching parents how to test milk and daily time testing milk. This outcome will include time (in hours) spent in the first 14 days for parent and staff, with a health economist determining costs for that time

    Time frame: First 14 days postpartum

  2. Establish feasibility of parent-led longitudinal parent milk Na testing in the first 14 days postpartum: parent acceptance via interviews

    We will collect qualitative data on parent acceptance and feelings about Na testing from parent interviews

    Time frame: First 14 days postpartum

  3. Establish feasibility of parent-led longitudinal parent milk Na testing in the first 14 days postpartum: parent acceptance via surveys

    We will collect qualitative data on parent acceptance and feelings about Na testing from parent surveys

    Time frame: First 14 days postpartum

Secondary outcomes

  1. Investigate inter-relationships between pumping frequency, parent lactation risk factors, daily milk Na levels and longer term lactation outcomes (milk provision at NICU discharge).

    We will assess interrelationships between aforementioned factors and milk provision at NICU discharge (exclusive, any, none). Note these are not necessarily correlations, but relationships and associations that we will analyze and explore in various models and combinations, so these outcome cannot be separated.

    Time frame: Enrollment to infant NICU discharge, up to 52 weeks (average NICU stay is about 10 weeks)

  2. Investigate inter-relationships between pumping frequency, parent lactation risk factors, daily milk Na and short term lactation outcomes (coming to volume)

    We will assess interrelationships between aforementioned factors and coming to volume (pumping at least 500mL/day by postpartum day 14).Note these are not necessarily correlations, but relationships and associations that we will analyze and explore in various models and combinations, so these outcomes cannot be separated.

    Time frame: First 14 days postpartum

Other outcomes

  1. Explore if POC Na data used to recommend changes in pumping behaviour is associated with actual changes in parent pumping behaviour

    Explore in parents whom we recommend to modify pumping frequency, rates of coming to volume by day 14 (pumping at least 500mL/day)

    Time frame: First 14 days postpartum

  2. Explore how POC Na data used to recommend changes in pumping behaviour is associated with short-term milk volumes

    Determine in parents whom we recommend to modify pumping frequency based on POC Na, how often they actually followed our recommendations

    Time frame: First 14 days postpartum

07

Study locations

2 of 2 sites recruiting
  • Seattle Children's Hospital
    Seattle, Washington 98105, United States
    Recruiting
  • University of Washington Medical Center - Montlake
    Seattle, Washington 98195, United States
    Recruiting
08

References and documents

Study documents

  • Protocol and statistical analysis plan · Jun 5, 2023

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06563726
Lead sponsor
The Hospital for Sick Children
Collaborators
University of Washington
Responsible party
Samantha Anthony (Health Clinician Scientist, Associate Professor, The Hospital for Sick Children) — Principal investigator
First posted
Aug 21, 2024
Start date
Mar 10, 2025
Primary completion
Dec 2025 (estimated)
Completion
Mar 2026 (estimated)
Last update
May 28, 2025

Study contacts

Samantha J. Anthony, PhD
Contact
samantha.anthony@sickkids.ca
(416) 813-7654 ext. 303126
Rebecca Hobban, MD, MPH
Contact
Rebecca.Hoban@seattlechildrens.org
Samantha J. Anthony, PhD
principal investigator · The Hospital for Sick Children

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion